ABSTRACT

Provided are 1-N-aminobenzimidazole derivatives represented by the following formula (I):



(I)

wherein R^1 and R^2 each represents a substituted or unsubstituted alkyl group or the like, R^3, R^5 and R^6 each represents an alkyl group, alkoxy group, hydrogen atom or the like, R^4 represents a substituted or unsubstituted alkyl group or the like, A represents a benzene ring or the like, B represents a hydrogen atom or the like, an n stands for an integer of from 0 to 2, or salts thereof; and medicines containing them.

The compounds (I) according to the present invention do not bring about much individual differences in therapeutic effects despite the existence of individual differences in the CYP2C19 activity. At the same dose, they can hence bring about appropriate therapeutic effects for all patients. In addition, they are low in the risk of induction of an interaction or a cancer caused by induction of the CYP1A family. Accordingly, they are useful as peptic ulcer therapeutic agents which are safe and surely bring about therapeutic effects.